全文获取类型
收费全文 | 3061篇 |
免费 | 245篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 82篇 |
妇产科学 | 46篇 |
基础医学 | 462篇 |
口腔科学 | 97篇 |
临床医学 | 203篇 |
内科学 | 651篇 |
皮肤病学 | 187篇 |
神经病学 | 161篇 |
特种医学 | 94篇 |
外科学 | 538篇 |
综合类 | 14篇 |
预防医学 | 147篇 |
眼科学 | 52篇 |
药学 | 202篇 |
中国医学 | 6篇 |
肿瘤学 | 343篇 |
出版年
2024年 | 3篇 |
2023年 | 24篇 |
2022年 | 46篇 |
2021年 | 89篇 |
2020年 | 59篇 |
2019年 | 66篇 |
2018年 | 84篇 |
2017年 | 86篇 |
2016年 | 93篇 |
2015年 | 98篇 |
2014年 | 126篇 |
2013年 | 128篇 |
2012年 | 223篇 |
2011年 | 231篇 |
2010年 | 122篇 |
2009年 | 131篇 |
2008年 | 178篇 |
2007年 | 190篇 |
2006年 | 175篇 |
2005年 | 156篇 |
2004年 | 145篇 |
2003年 | 135篇 |
2002年 | 130篇 |
2001年 | 42篇 |
2000年 | 38篇 |
1999年 | 38篇 |
1998年 | 41篇 |
1997年 | 28篇 |
1996年 | 25篇 |
1995年 | 29篇 |
1994年 | 19篇 |
1993年 | 19篇 |
1992年 | 40篇 |
1991年 | 42篇 |
1990年 | 42篇 |
1989年 | 41篇 |
1988年 | 35篇 |
1987年 | 35篇 |
1986年 | 24篇 |
1985年 | 12篇 |
1984年 | 10篇 |
1983年 | 11篇 |
1982年 | 2篇 |
1980年 | 3篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1974年 | 3篇 |
1969年 | 3篇 |
排序方式: 共有3323条查询结果,搜索用时 656 毫秒
101.
102.
103.
104.
105.
Kajiume T Sera Y Kawahara Y Matsumoto M Fukazawa T Imura T Yuge L Kobayashi M 《Experimental hematology》2012,40(9):751-760.e1
The Polycomb-group complex is a chromatin regulatory factor that is classified into two different complexes: Polycomb repressive complex 1 and 2. Components of Polycomb repressive complex 1 are involved in the self-renewal of hematopoietic stem cells. Bmi1, one of these components, maintains the immaturity of neural and cancer stem cells as well as that of hematopoietic stem cells. We constructed recombinant protein transduction domain (PTD)-Polycomb proteins and transduced them into murine bone marrow (BM) cells. We designed and fused the PTD-protein transduction domain to three proteins (i.e., green fluorescent protein, Bmi1, and Mel18). Murine BM cells were incubated for 48 h and each PTD-Polycomb protein was added. Then, we analyzed the function of hematopoiesis using the colony assay and transplantation. BM cells exposed to PTD-Bmi1 showed an increased number of colonies. In contrast, BM cells exposed to PTD-Mel18 or to both proteins showed a decreased number of colonies. Hematopoietic cells derived from PTD-Bmi1-transduced BM cells were significantly increased in the peripheral blood at 6 weeks after transplantation. Moreover, 80% of mice transplanted with PTD-Bmi1-transduced BM cells died at 8 to 24 weeks after transplantation. However, only a few early deaths were observed in the mice transplanted with BM cells exposed to both PTD-Bmi1 and PTD-Mel18. We expect that hematopoietic stem cells could proliferate after transduction with PTD-Bmi1, but this may generate undesirable effects, e.g., tumorigenesis. Thus, Bmi1 and Mel18 have opposing functions and are present in distinct complexes. 相似文献
106.
107.
Kohei Hosokawa Takamasa Katagiri Naomi Sugimori Ken Ishiyama Yumi Sasaki Yu Seiki Aiko Sato-Otsubo Masashi Sanada Seishi Ogawa Shinji Nakao 《Haematologica》2012,97(12):1845-1849
To characterize bone marrow failure with del(13q), we reviewed clinical records of 22 bone marrow failure patients possessing del(13q) alone or del(13q) plus other abnormalities. All del(13q) patients were diagnosed with myelodysplastic syndrome-unclassified due to the absence of apparent dysplasia. Elevated glycosylphosphatidylinositol-anchored protein-deficient blood cell percentages were detected in all 16 with del(13q) alone and 3 of 6 (50%) patients with del(13q) plus other abnormalities. All 14 patients with del(13q) alone and 2 of 5 (40%) patients with del(13q) plus other abnormalities responded to immunosuppressive therapy with 10-year overall survival rates of 83% and 67%, respectively. Only 2 patients who had abnormalities in addition to the del(13q) abnormality developed acute myeloid leukemia. Given that myelodysplastic syndrome-unclassified with del(13q) is a benign bone marrow failure subset characterized by good response to immunosuppressive therapy and a high prevalence of increased glycosylphosphatidylinositol-anchored protein-deficient cells, del(13q) should not be considered an intermediate-risk chromosomal abnormality.Key words: glycosylphosphatidylinositol-anchored protein-deficient, cells, bone marrow failure, 13q deletion, immunosuppressive therapy 相似文献
108.
K Kawasaki H Kobayashi K Kurahara Y Oshiro H Ishibashi K Kominato S Kochi M Funata Y Okamoto A Saka Y Nagata Y Sakai T Yao T Fuchigami 《Nihon Shokakibyo Gakkai zasshi》2012,109(9):1546-1555
We reviewed 428 subjects with colorectal serrated lesions resected endoscopically or surgically at our institution. Colorectal serrated lesions were pathologically divided into 3 groups: hyperplastic polyp (HP), sessile serrated adenoma/polyp (SSA/P), and traditional serrated adenoma (TSA). SSA/P was detected frequently in the right colon and SSA/P was mainly flat-elevated. Cancers occurring in SSA/P were found more frequently than HP or TSA. The incidence of cancer in SSA/P was equivalent to that of cancer in traditional adenoma. Further studies are warranted to clarify clinicopathological features of serrated lesions of the colorectum. 相似文献
109.
Manoel J. Teixeira Massako Okada Ana Sofia Cueva Moscoso Mariana Yumi Takahashi Puerta Lin T. Yeng Ricardo Galhardoni Sérgio Tengan Daniel Ciampi de Andrade 《Clinics (S?o Paulo, Brazil)》2013,68(7):1057-1060
OBJECTIVE:
This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens.METHODS:
This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699RESULTS:
Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments.CONCLUSIONS:
Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies. 相似文献110.